Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors

Kazuhiko Kobayashi, Masahiro Kami, Naoko Murashige, Eiji Kusumi, Yukiko Kishi, Tamae Hamaki, Akiko Hori, Tomoko Matsumura, Koichiro Yuji, Shigeru Masuo, Shinichiro Mori, Shigesaburo Miyakoshi, Ryuji Tanosaki, Tadayuki Mitamura, Yoichi Takaue, Shuichi Taniguchi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The characteristics of relapse following reduced-intensity stem-cell transplantation (RIST) remain to be clarified. We reviewed the medical records of 19 patients with acute leukaemia [acute myeloid leukaemia (AML), 16; acute lymphoblastic leukaemia (ALL), 3] who relapsed after RIST from related donors using purine-analogue-based regimens. Their median age was 55 years (range, 29-65 years). Median interval between RIST and relapse was 4.9 months (range, 1.8-24.9 months). Three chose not to receive interventions. The remaining 16 patients received withdrawal of immunosuppression (n = 3), chemotherapy (n = 2), donor lymphocyte infusion (n = 10) and second transplantation (n = 7), alone (n = 9) or in combination (n = 7). Four are alive with a median follow-up of 27.6 months (range, 16.0-28.9 months); three in remission and one in relapse. The 2-year overall survival after relapse was 28.9%. Causes of death in 15 patients included progressive disease (n = 7), graft-versus-host disease (n = 5) and infections (n = 3). Cumulative incidences of relapse-related and non-relapse-related deaths at 2 years after relapse were 37% and 32% respectively. Two prognostic factors were identified on univariate analysis: age [P = 0.017; hazard ratio (HR), 1.16; 95% confidence interval (CI), 1.03-1.32], and ALL as underlying disease (P = 0.011; HR, 10.4; 95% CI, 1.73-62.4). Some AML patients who relapse after RIST achieve durable remission with allogeneic immunotherapy-based interventions; however they carry a significant risk of non-relapse mortality.

Original languageEnglish
Pages (from-to)795-802
Number of pages8
JournalBritish Journal of Haematology
Volume129
Issue number6
DOIs
Publication statusPublished - 2005 Jun
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Leukemia
Tissue Donors
Antigens
Recurrence
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Confidence Intervals
Graft vs Host Disease
Immunotherapy
Immunosuppression
Medical Records
Cause of Death
Transplantation
Lymphocytes
Drug Therapy
Survival
Mortality
Incidence
Infection

Keywords

  • Donor lymphocyte infusion
  • Graft-versus-host disease
  • Graft-versus-leukaemia effect
  • Non-myeloablative haematopoietic stem cell transplantation
  • Second allogeneic transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors. / Kobayashi, Kazuhiko; Kami, Masahiro; Murashige, Naoko; Kusumi, Eiji; Kishi, Yukiko; Hamaki, Tamae; Hori, Akiko; Matsumura, Tomoko; Yuji, Koichiro; Masuo, Shigeru; Mori, Shinichiro; Miyakoshi, Shigesaburo; Tanosaki, Ryuji; Mitamura, Tadayuki; Takaue, Yoichi; Taniguchi, Shuichi.

In: British Journal of Haematology, Vol. 129, No. 6, 06.2005, p. 795-802.

Research output: Contribution to journalArticle

Kobayashi, K, Kami, M, Murashige, N, Kusumi, E, Kishi, Y, Hamaki, T, Hori, A, Matsumura, T, Yuji, K, Masuo, S, Mori, S, Miyakoshi, S, Tanosaki, R, Mitamura, T, Takaue, Y & Taniguchi, S 2005, 'Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors', British Journal of Haematology, vol. 129, no. 6, pp. 795-802. https://doi.org/10.1111/j.1365-2141.2005.05533.x
Kobayashi, Kazuhiko ; Kami, Masahiro ; Murashige, Naoko ; Kusumi, Eiji ; Kishi, Yukiko ; Hamaki, Tamae ; Hori, Akiko ; Matsumura, Tomoko ; Yuji, Koichiro ; Masuo, Shigeru ; Mori, Shinichiro ; Miyakoshi, Shigesaburo ; Tanosaki, Ryuji ; Mitamura, Tadayuki ; Takaue, Yoichi ; Taniguchi, Shuichi. / Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors. In: British Journal of Haematology. 2005 ; Vol. 129, No. 6. pp. 795-802.
@article{a29629ec37a24238908f8d68101ee414,
title = "Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors",
abstract = "The characteristics of relapse following reduced-intensity stem-cell transplantation (RIST) remain to be clarified. We reviewed the medical records of 19 patients with acute leukaemia [acute myeloid leukaemia (AML), 16; acute lymphoblastic leukaemia (ALL), 3] who relapsed after RIST from related donors using purine-analogue-based regimens. Their median age was 55 years (range, 29-65 years). Median interval between RIST and relapse was 4.9 months (range, 1.8-24.9 months). Three chose not to receive interventions. The remaining 16 patients received withdrawal of immunosuppression (n = 3), chemotherapy (n = 2), donor lymphocyte infusion (n = 10) and second transplantation (n = 7), alone (n = 9) or in combination (n = 7). Four are alive with a median follow-up of 27.6 months (range, 16.0-28.9 months); three in remission and one in relapse. The 2-year overall survival after relapse was 28.9{\%}. Causes of death in 15 patients included progressive disease (n = 7), graft-versus-host disease (n = 5) and infections (n = 3). Cumulative incidences of relapse-related and non-relapse-related deaths at 2 years after relapse were 37{\%} and 32{\%} respectively. Two prognostic factors were identified on univariate analysis: age [P = 0.017; hazard ratio (HR), 1.16; 95{\%} confidence interval (CI), 1.03-1.32], and ALL as underlying disease (P = 0.011; HR, 10.4; 95{\%} CI, 1.73-62.4). Some AML patients who relapse after RIST achieve durable remission with allogeneic immunotherapy-based interventions; however they carry a significant risk of non-relapse mortality.",
keywords = "Donor lymphocyte infusion, Graft-versus-host disease, Graft-versus-leukaemia effect, Non-myeloablative haematopoietic stem cell transplantation, Second allogeneic transplantation",
author = "Kazuhiko Kobayashi and Masahiro Kami and Naoko Murashige and Eiji Kusumi and Yukiko Kishi and Tamae Hamaki and Akiko Hori and Tomoko Matsumura and Koichiro Yuji and Shigeru Masuo and Shinichiro Mori and Shigesaburo Miyakoshi and Ryuji Tanosaki and Tadayuki Mitamura and Yoichi Takaue and Shuichi Taniguchi",
year = "2005",
month = "6",
doi = "10.1111/j.1365-2141.2005.05533.x",
language = "English",
volume = "129",
pages = "795--802",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors

AU - Kobayashi, Kazuhiko

AU - Kami, Masahiro

AU - Murashige, Naoko

AU - Kusumi, Eiji

AU - Kishi, Yukiko

AU - Hamaki, Tamae

AU - Hori, Akiko

AU - Matsumura, Tomoko

AU - Yuji, Koichiro

AU - Masuo, Shigeru

AU - Mori, Shinichiro

AU - Miyakoshi, Shigesaburo

AU - Tanosaki, Ryuji

AU - Mitamura, Tadayuki

AU - Takaue, Yoichi

AU - Taniguchi, Shuichi

PY - 2005/6

Y1 - 2005/6

N2 - The characteristics of relapse following reduced-intensity stem-cell transplantation (RIST) remain to be clarified. We reviewed the medical records of 19 patients with acute leukaemia [acute myeloid leukaemia (AML), 16; acute lymphoblastic leukaemia (ALL), 3] who relapsed after RIST from related donors using purine-analogue-based regimens. Their median age was 55 years (range, 29-65 years). Median interval between RIST and relapse was 4.9 months (range, 1.8-24.9 months). Three chose not to receive interventions. The remaining 16 patients received withdrawal of immunosuppression (n = 3), chemotherapy (n = 2), donor lymphocyte infusion (n = 10) and second transplantation (n = 7), alone (n = 9) or in combination (n = 7). Four are alive with a median follow-up of 27.6 months (range, 16.0-28.9 months); three in remission and one in relapse. The 2-year overall survival after relapse was 28.9%. Causes of death in 15 patients included progressive disease (n = 7), graft-versus-host disease (n = 5) and infections (n = 3). Cumulative incidences of relapse-related and non-relapse-related deaths at 2 years after relapse were 37% and 32% respectively. Two prognostic factors were identified on univariate analysis: age [P = 0.017; hazard ratio (HR), 1.16; 95% confidence interval (CI), 1.03-1.32], and ALL as underlying disease (P = 0.011; HR, 10.4; 95% CI, 1.73-62.4). Some AML patients who relapse after RIST achieve durable remission with allogeneic immunotherapy-based interventions; however they carry a significant risk of non-relapse mortality.

AB - The characteristics of relapse following reduced-intensity stem-cell transplantation (RIST) remain to be clarified. We reviewed the medical records of 19 patients with acute leukaemia [acute myeloid leukaemia (AML), 16; acute lymphoblastic leukaemia (ALL), 3] who relapsed after RIST from related donors using purine-analogue-based regimens. Their median age was 55 years (range, 29-65 years). Median interval between RIST and relapse was 4.9 months (range, 1.8-24.9 months). Three chose not to receive interventions. The remaining 16 patients received withdrawal of immunosuppression (n = 3), chemotherapy (n = 2), donor lymphocyte infusion (n = 10) and second transplantation (n = 7), alone (n = 9) or in combination (n = 7). Four are alive with a median follow-up of 27.6 months (range, 16.0-28.9 months); three in remission and one in relapse. The 2-year overall survival after relapse was 28.9%. Causes of death in 15 patients included progressive disease (n = 7), graft-versus-host disease (n = 5) and infections (n = 3). Cumulative incidences of relapse-related and non-relapse-related deaths at 2 years after relapse were 37% and 32% respectively. Two prognostic factors were identified on univariate analysis: age [P = 0.017; hazard ratio (HR), 1.16; 95% confidence interval (CI), 1.03-1.32], and ALL as underlying disease (P = 0.011; HR, 10.4; 95% CI, 1.73-62.4). Some AML patients who relapse after RIST achieve durable remission with allogeneic immunotherapy-based interventions; however they carry a significant risk of non-relapse mortality.

KW - Donor lymphocyte infusion

KW - Graft-versus-host disease

KW - Graft-versus-leukaemia effect

KW - Non-myeloablative haematopoietic stem cell transplantation

KW - Second allogeneic transplantation

UR - http://www.scopus.com/inward/record.url?scp=21344474561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344474561&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2005.05533.x

DO - 10.1111/j.1365-2141.2005.05533.x

M3 - Article

VL - 129

SP - 795

EP - 802

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -